IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+11.71%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$302M
AUM Growth
+$302M
(-1.5%)
Cap. Flow
-$35.1M
Cap. Flow
% of AUM
-11.6%
Top 10 Holdings %
Top 10 Hldgs %
44.95%
Holding
160
New
20
Increased
14
Reduced
32
Closed
33
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$10.5M |
| 2 |
Apogee Therapeutics
APGE
|
$10.1M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$8.15M |
| 4 |
Insmed
INSM
|
$7.95M |
| 5 |
Cogent Biosciences
COGT
|
$7.44M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$11.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$10.1M |
| 4 |
Lyra Therapeutics
LYRA
|
$9.29M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$7.86M |
Sector Composition
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cidara Therapeutics
CDTX
$1.66B
| $22.6M | 4.35% | 464,488 +215,548 | +87% | +$10.5M |
|
|
2
Alnylam Pharmaceuticals
ALNY
$58.5B
| $18.5M | 3.54% | 56,594 +25,000 | +79% | +$8.15M |
|
|
3
Insmed
INSM
$28.8B
| $16.5M | 3.17% | 163,751 +78,951 | +93% | +$7.95M |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $13.9M | 2.67% | 146,831 +16,831 | +13% | +$1.59M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $12.5M | 2.39% | 433,431 -90,000 | -17% | -$2.59M |
|
6
Akero Therapeutics
AKRO
$3.74B
| $11.7M | 2.25% | 220,000 -25,000 | -10% | -$1.33M |
|
7
Praxis Precision Medicines
PRAX
$958M
| $11.6M | 2.24% | 276,950 +131,448 | +90% | +$5.53M |
|
|
8
Apogee Therapeutics
APGE
$2.17B
| $10.1M | 1.94% | +232,047 | New | +$10.1M |
|
9
Vaxcyte
PCVX
$4B
| $9.92M | 1.9% | 305,000 +105,000 | +53% | +$3.41M |
|
|
ACOG
10
Alpha Cognition Inc. Common Stock
ACOG
$134M
| $8.56M | 1.64% | 917,867 -50,000 | -5% | -$467K |
|
|
11
Tarsus Pharmaceuticals
TARS
$2.47B
| $7.96M | 1.53% | 196,536 -288,485 | -59% | -$11.7M |
|
12
Cytokinetics
CYTK
$4.23B
| $7.71M | 1.48% | 233,464 +83,482 | +56% | +$2.76M |
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $7.68M | 1.48% | 449,087 +280,000 | +166% | +$4.79M |
|
14
TG Therapeutics
TGTX
$4.65B
| $7.56M | 1.45% | 209,938 -127 | -0.1% | -$4.57K |
|
|
15
Cogent Biosciences
COGT
$1.69B
| $7.44M | 1.43% | +1,035,528 | New | +$7.44M |
|
16
Viridian Therapeutics
VRDN
$1.5B
| $6.57M | 1.26% | 469,949 -25,000 | -5% | -$350K |
|
17
Arvinas
ARVN
$568M
| $6.26M | 1.2% | 850,000 +620,100 | +270% | +$4.56M |
|
18
Forte Biosciences
FBRX
$137M
| $6.16M | 1.18% | 476,443 -132,782 | -22% | -$1.72M |
|
19
Vir Biotechnology
VIR
$686M
| $5.38M | 1.03% | 1,068,062 | – | – |
|
20
Catalyst Pharmaceutical
CPRX
$2.52B
| $4.55M | 0.87% | 209,649 -40,000 | -16% | -$868K |
|
21
Delcath Systems
DCTH
$385M
| $4.38M | 0.84% | 322,390 +222,025 | +221% | +$3.02M |
|
22
Jazz Pharmaceuticals
JAZZ
$7.75B
| $4.24M | 0.82% | +40,000 | New | +$4.24M |
|
23
CG Oncology
CGON
$2.04B
| $4.03M | 0.77% | +155,000 | New | +$4.03M |
|
24
Neuronetics
STIM
$220M
| $3.84M | 0.74% | 1,099,700 -300 | -0% | -$1.05K |
|
25
Structure Therapeutics
GPCR
$1.11B
| $3.8M | 0.73% | 183,085 -81,000 | -31% | -$1.68M |
|